Answers are grounded in this paper and cite their sources.
Objective: To investigate the effects of haloperidol vs. placebo on long-term cognitive function in formerly critically ill patients with ICU delirium, 1 year after randomization in the Agents Intervening against Delirium in the ICU (AID-ICU) randomized clinical trial. Design: Pre-planned 1-year follow-up of the AID-ICU trial conducted from June 2019 to April 2023. Setting: Three university-affiliated ICUs in Denmark. Patients: Adult ICU patients previously enrolled in the AID-ICU trial. Interventions: Patients in the AID-ICU were randomized to either haloperidol or placebo (0.9% saline) when treated for delirium in the ICU. Measurements and Main Results: The primary outcome was global cognitive function at 1 year, assessed using Repeatable Battery for the Assessment of Neuropsychologic Status (RBANS) Global Index Score Secondary outcomes including domain-specific RBANS scores and executive function, measured by the Trail Making Test A and B. Analyses used the intention-to-treat population. Non-survivors were assigned the lowest possible score on each outcome, reflecting death as a competing outcome. Missing data among survivors were handled using multiple imputations. Of the 632 randomized patients, 624 were included. Cognitive outcome data were available for 134 of 343 surviving patients: 67 in the haloperidol group and 67 in the placebo group. Median global cognitive scores were 40 (interquartile range [IQR]: 40–75) in the haloperidol group and 40 (IQR: 40–72) in the placebo group (mean difference: 2; 95% CI, –3 to 7; p = 0.48). No significant differences were observed in secondary outcomes. Given the high proportion of missing data, best-worst and worst-best sensitivity analyses were performed, yielding estimates in opposite directions. Conclusions: In this 1-year follow-up of the AID-ICU treatment with haloperidol for delirium in the ICU was not associated with improved long-term cognitive function compared with placebo. However, given the extent of missing outcome data and the divergent results of our sensitivity analyses, this estimate should be interpreted as imprecise rather than conclusive; clinically relevant effects of pharmacologic delirium treatment on cognition cannot be excluded, and future adequately powered studies with more complete follow-up are warranted.
No takes yet. Share an insight, caveat, or question.
Mortensen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: